Compare Amylx Pharmaceuticals Inc (AMLX) vs Lemonade Inc (LMND) Price & Performance

AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.

Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.

Lemonade (LMND) trades at $52.68, down 0.49% on the day, with technical indicators showing a bearish bias. The company reported Q2 2026 revenue growth of 79% year-over-year and has beaten EPS estimates for three consecutive quarters, yet remains unprofitable with a net income margin of -22.43% in 2025. Recent news highlights management's presentation at an Oppenheimer conference and ongoing expansion of renters insurance products.

The outlook is mixed; accelerating premium growth and a path to positive adjusted EBITDA by Q4 2026 offer upside potential, but high valuation multiples, persistent losses, and bearish technical signals present significant risks. Analyst consensus is evenly split, reflecting uncertainty around the profitability timeline.